Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Inhibition of in vitro leukotriene B4 biosynthesis in human neutrophil granulocytes and docking studies of natural quinones

P. Landa, Z. Kutil, V. Temml, J. Malik, L. Kokoska, U. Widowitz, M. Pribylova, M. Dvorakova, P. Marsik, D. Schuster, R. Bauer, T. Vanek,

. 2013 ; 8 (1) : 105-8.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Quinones are compounds frequently contained in medicinal plants used for the treatment of inflammatory diseases. Therefore, the impact of plant-derived quinones on the arachidonic acid metabolic pathway is worthy of investigation. In this study, twenty-three quinone compounds of plant origin were tested in vitro for their potential to inhibit leukotriene B4 (LTB4) biosynthesis in activated human neutrophil granulocytes with 5-lipoxygenase (5-LOX) activity. The benzoquinones primin (3) and thymohydroquinone (4) (IC50 = 4.0 and 4.1 microM, respectively) showed activity comparable with the reference inhibitor zileuton (1C50 = 4.1 microM). Moderate activity was observed for the benzoquinone thymoquinone (2) (1C50 = 18.2 microM) and the naphthoquinone shikonin (1) (IC50 = 24.3 microM). The anthraquinone emodin and the naphthoquinone plumbagin (5) displayed only weak activities (IC50 > 50 microM). The binding modes of the active compounds were further evaluated in silico by molecular docking to the human 5-LOX crystal structure. This process supports the biological data and suggested that, although the redox potential is responsible for the quinone's activity on multiple targets, in the case of 5-LOX the molecular structure plays a vital role in the inhibition. The obtained results suggest primin as a promising compound for the development of dual COX-2/5-LOX inhibitors.

000      
00000naa a2200000 a 4500
001      
bmc13023941
003      
CZ-PrNML
005      
20130710100814.0
007      
ta
008      
130703s2013 xxu f 000 0|eng||
009      
AR
035    __
$a (PubMed)23472470
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Landa, Premysl $u Laboratory of Plant Biotechnologies, Institute of Experimental Botany AS CR, v.v.i., 165 02 Prague 6 - Lysolaje, Czech Republic. landa@ueb.cas.cz
245    10
$a Inhibition of in vitro leukotriene B4 biosynthesis in human neutrophil granulocytes and docking studies of natural quinones / $c P. Landa, Z. Kutil, V. Temml, J. Malik, L. Kokoska, U. Widowitz, M. Pribylova, M. Dvorakova, P. Marsik, D. Schuster, R. Bauer, T. Vanek,
520    9_
$a Quinones are compounds frequently contained in medicinal plants used for the treatment of inflammatory diseases. Therefore, the impact of plant-derived quinones on the arachidonic acid metabolic pathway is worthy of investigation. In this study, twenty-three quinone compounds of plant origin were tested in vitro for their potential to inhibit leukotriene B4 (LTB4) biosynthesis in activated human neutrophil granulocytes with 5-lipoxygenase (5-LOX) activity. The benzoquinones primin (3) and thymohydroquinone (4) (IC50 = 4.0 and 4.1 microM, respectively) showed activity comparable with the reference inhibitor zileuton (1C50 = 4.1 microM). Moderate activity was observed for the benzoquinone thymoquinone (2) (1C50 = 18.2 microM) and the naphthoquinone shikonin (1) (IC50 = 24.3 microM). The anthraquinone emodin and the naphthoquinone plumbagin (5) displayed only weak activities (IC50 > 50 microM). The binding modes of the active compounds were further evaluated in silico by molecular docking to the human 5-LOX crystal structure. This process supports the biological data and suggested that, although the redox potential is responsible for the quinone's activity on multiple targets, in the case of 5-LOX the molecular structure plays a vital role in the inhibition. The obtained results suggest primin as a promising compound for the development of dual COX-2/5-LOX inhibitors.
650    _2
$a antiflogistika $x analýza $7 D000893
650    _2
$a benzochinony $x farmakologie $7 D016227
650    _2
$a inhibitory cyklooxygenasy 2 $x analýza $7 D052246
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    _2
$a lidé $7 D006801
650    _2
$a leukotrien B4 $x antagonisté a inhibitory $x biosyntéza $7 D007975
650    _2
$a inhibitory lipoxygenas $x analýza $7 D016859
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a neutrofily $x účinky léků $x metabolismus $7 D009504
650    _2
$a rostlinné extrakty $x chemie $x farmakologie $7 D010936
650    _2
$a léčivé rostliny $x chemie $7 D010946
650    _2
$a chinony $x farmakologie $7 D011809
650    _2
$a thymol $x analogy a deriváty $x farmakologie $7 D013943
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kutil, Zsofia $u -
700    1_
$a Temml, Veronika $u -
700    1_
$a Malik, Jan $u -
700    1_
$a Kokoska, Ladislav $u -
700    1_
$a Widowitz, Ute $u -
700    1_
$a Pribylova, Marie $u -
700    1_
$a Dvorakova, Marcela $u -
700    1_
$a Marsik, Petr $u -
700    1_
$a Schuster, Daniela $u -
700    1_
$a Bauer, Rudolf $u -
700    1_
$a Vanek, Tomas $u -
773    0_
$w MED00180450 $t Natural product communications $x 1934-578X $g Roč. 8, č. 1 (2013), s. 105-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23472470 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20130710101237 $b ABA008
999    __
$a ok $b bmc $g 987621 $s 822321
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 8 $c 1 $d 105-8 $i 1934-578X $m Natural product communications $n Nat Prod Commun $x MED00180450
LZP    __
$a Pubmed-20130703

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...